VOTRIENT� (pazopanib) tablets is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
VOTRIENT� (pazopanib) tablets is indicated for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitation of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.
Important Safety Information for VOTRIENT� (pazopanib) tablets
Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended.
Contains 30 Tablets.